Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

1,413 trials

NCT07783607
Not yet recruiting
MM-CARE: Cardiovascular Risk Assessment in Adults With Multiple Myeloma
Not applicable · US · 1 site
Registry update: 25 Aug 2026
Fresh (updated 2 months ago)
NCT06435910
Not yet recruiting
Engineered Dendritic Cell Vaccines for Multiple Myeloma
Phase 1 · CN · 1 site
Registry update: 2 Nov 2026
Fresh (updated this month)
NCT06006741
Not yet recruiting
Universal CAR-T Cells Targeting Multiple Myeloma
Phase 1 · CN · 1 site
Registry update: 2 Nov 2026
Fresh (updated this month)
NCT06948084
Recruiting
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Phase 2 · US · 32 sites
Registry update: 4 Nov 2026
Fresh (updated this month)
NCT07463807
Recruiting
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
Phase 1/2 · US · 1 site
Registry update: 16 Oct 2026
Fresh (updated this month)
NCT07474961
Not yet recruiting
BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases.
Phase 4 · DK · 5 sites
Registry update: 16 Mar 2026
Ageing (updated 7 months ago)
NCT07029776
Not yet recruiting
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
Phase 2 · US · 1 site
Registry update: 2 Sept 2026
Fresh (updated 2 months ago)
NCT07842198
Not yet recruiting
Restrictive Versus Standard Antibiotic Treatment During CAR-T Therapy
Phase 2 · DK · 1 site
Registry update: 25 Sept 2026
Fresh (updated 1 month ago)
NCT07871747
Not yet recruiting
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
Phase 1 · US · 1 site
Registry update: 22 Oct 2026
Fresh (updated this month)
NCT07903506
Not yet recruiting
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
Phase 3 · - · no sites listed
Registry update: 29 Oct 2026
Fresh (updated this month)
NCT07887672
Not yet recruiting
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
Phase 3 · - · no sites listed
Registry update: 21 Oct 2026
Fresh (updated this month)
NCT07848672
Not yet recruiting
Early Prophylactic rhTPO Administration for Thrombocytopenia Associated With EAP Regimen-Based Hematopoietic Stem Cell Mobilization
Phase 2/3 · - · no sites listed
Registry update: 30 Sept 2026
Fresh (updated 1 month ago)
NCT07732712
Not yet recruiting
Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells
Phase 2/3 · - · no sites listed
Registry update: 2 Oct 2026
Fresh (updated 1 month ago)
NCT03271632
Not yet recruiting
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
Phase 1/2 · CN · 1 site
Registry update: 30 Oct 2026
Fresh (updated this month)
NCT06429150
Not yet recruiting
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Phase 1/2 · CN · 1 site
Registry update: 2 Nov 2026
Fresh (updated this month)
NCT07887984
Not yet recruiting
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
Phase 2/3 · - · no sites listed
Registry update: 22 Oct 2026
Fresh (updated this month)
NCT07903272
Not yet recruiting
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
Phase 3 · - · no sites listed
Registry update: 4 Nov 2026
Fresh (updated this month)
NCT07600151
Not yet recruiting
Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma
Phase 1/2 · DE · 1 site
Registry update: 20 May 2026
Fresh (updated 5 months ago)
NCT07771361
Not yet recruiting
BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma
Phase 2 · - · no sites listed
Registry update: 18 Aug 2026
Fresh (updated 2 months ago)
NCT07831122
Not yet recruiting
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Phase 1 · CA · 7 sites
Registry update: 21 Sept 2026
Fresh (updated 1 month ago)

Ordered by registry start date. Freshness and sponsorship never change the order.